Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Recruiting	Phase 1 / Phase 2	2026-04-14		NCT06561152

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Stanford University	620
Stemline Therapeutics, Inc.	22

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Stanford University	Palo Alto	United States	161

Clinical trials